Caring Ambassadors Program

Hepatitis C Newsletter

www.HepCChallenge.org

DECEMBER 2012

Clinical Trials, Cohort Studies, Pilot Studies

Sexual transmission of HCV among monogamous heterosexual couples: The HCV partners study. Terrault NA, Dodge JL, Murphy EL, et al. Hepatology. 2012 Nov 23. doi: 10.1002/hep.26164. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23175457

Comprehensive analysis for viral elements and interleukin-28B polymorphisms in response to pegylated interferon plus ribavirin therapy in hepatitis C virus 1B infection. Maekawa S, Sakamoto M, Miura M, et al. Hepatology. 2012 Nov;56(5):1611-21. doi: 10.1002/hep.25826.

http://www.ncbi.nlm.nih.gov/pubmed/22577043

Efficacy and safety of ribavirin plus pegylated interferon alfa in geriatric patients with chronic hepatitis C. Hu CC, Lin CL, et al. Aliment Pharmacol Ther. 2012 Nov 5. doi: 10.1111/apt.12112. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23121150

Improved Inflammatory Activity With Peginterferon Alfa-2b Maintenance Therapy in Non-cirrhotic Prior Nonresponders: a Randomized Study. Poynard T, Bruix J, Schiff ER, et al. J Hepatol. 2012 Nov 14. pii: S0168-8278(12)00831-8. doi: 10.1016/j.jhep.2012.11.001. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23159770

Severe Neutropenia in Patients with Chronic Hepatitis C: A Benign Condition. Sheehan V, Weir A, Waters B. Acta Haematol. 2012 Nov 21;129(2):96-100. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23171914

Dual Oral Therapy with Daclatasvir and Asunaprevir for Patients with HCV Genotype 1b Infection and Limited Treatment Options. Suzuki Y, Ikeda K, Suzuki F, et al. J Hepatol. 2012 Nov 23. pii: S0168-8278(12)00881-1. doi: 10.1016/j.jhep.2012.09.037. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23183526

Sustained virologic response rates with telaprevir by response after 4 weeks of lead-in therapy in patients with prior treatment failure. Foster GR, Zeuzem S, Andreone P, et al. J Hepatol. 2012 Nov 23. pii: S0168-8278(12)00882-3. doi: 10.1016/j.jhep.2012.11.013. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23183521

Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naďve patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial. Rodriguez-Torres M, Lawitz E, Kowdley KV, et al. J Hepatol. 2012 Nov 23. pii: S0168-8278(12)00887-2. doi: 10.1016/j.jhep.2012.11.018. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23183528

Significance of a reduction in HCV RNA levels at 4 and 12 weeks in patients infected with HCV genotype 1b for the prediction of the outcome of combination therapy with peginterferon and ribavirin. Toyoda H, Kumada T, Shimada N, et al. BMC Infect Dis. 2012 Nov 27;12(1):324. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23181537

Exploratory study on telaprevir given every 8 h at 500 mg or 750 mg with peginterferon-alpha-2b and ribavirin in hepatitis C patients. Suzuki F, Suzuki Y, Sezaki H, et al. Hepatol Res. 2012 Nov 29. doi: 10.1111/hepr.12009. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23190247

Estimates of HCV-1 Patients Attaining RVR Following Dual Therapy with Peg-Interferon and Ribavirin. Andriulli A, Iacobellis A, Valvano MR, et al. Dig Dis Sci. 2012 Nov 28. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23187978

HCV genotype 1a shows a better virological response to antiviral therapy than HCV genotype 1b. Pellicelli AM, Romano M, Stroffolini T, et al. BMC Gastroenterol. 2012 Nov 16;12(1):162. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23157720

Basic and Applied Science, Pre-Clinical Studies

Innate Immune Tolerance and the Role of Kupffer Cells in Differential Responses to Interferon Therapy Among Patients with HCV Genotype 1 Infection. Lau DT, Negash A, Chen J, et al. Gastroenterology. 2012 Nov 1. pii: S0016-5085(12)01602-2. doi: 10.1053/j.gastro.2012.10.044. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23123437

Genetic polymorphisms of ICAM 1 and IL28 as predictors of liver fibrosis severity and viral clearance in hepatitis C genotype 4. Rizk NM, Derbala MF. Clin Res Hepatol Gastroenterol. 2012 Nov 5. pii: S2210-7401(12)00259-8. doi: 10.1016/j.clinre.2012.09.012. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23137758

Association of serum adipocytokines with insulin resistance and liver injury in patients with chronic hepatitis C genotype 4. Khattab MA, Eslam M, Aly MM, et al. J Clin Gastroenterol. 2012 Nov;46(10):871-9. doi: 10.1097/MCG.0b013e318256b68a.

http://www.ncbi.nlm.nih.gov/pubmed/22664476

Using Chimeric Mice with Humanized Livers to Predict Human Drug Metabolism and a Drug-Drug Interaction. Nishimura T, Hu Y, Wu M, et al. J Pharmacol Exp Ther. 2012 Nov 8. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23143674

HIV/HCV Coinfection

Effects of Angiotensin Converting Enzyme Inhibitors on Liver Fibrosis in HIV and Hepatitis C Coinfection. Reese LJ, Tider DS, Stivala AC, Fishbein DA. AIDS Res Treat. 2012;2012:978790. doi: 10.1155/2012/978790. Epub 2012 Nov 1.

http://www.ncbi.nlm.nih.gov/pubmed/23193466

Generalized Linear Model (GLM) framework for the association of host variables and viral strains with liver fibrosis in HCV/HIV coinfected patients. Matas M, Picornell A, Cifuentes C, et al. Infect Genet Evol. 2012 Nov 19. pii: S1567-1348(12)00354-1. doi: 10.1016/j.meegid.2012.10.020. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23174528

Racial/Ethnic Differences in Spontaneous HCV Clearance in HIV Infected and Uninfected Women. Sarkar M, Bacchetti P, Tien P, et al. Dig Dis Sci. 2012 Nov 24. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23179159

Pharmacogenetics of Efficacy and Safety of HCV Treatment in HCV-HIV Coinfected Patients: Significant Associations with IL28B and SOCS3 Gene Variants. Vidal F, López-Dupla M, Laguno M, et al. PLoS One. 2012;7(11):e47725. doi: 10.1371/journal.pone.0047725. Epub 2012 Nov 2.

http://www.ncbi.nlm.nih.gov/pubmed/23133602

HCV coinfection possibly promotes left ventricular dysfunction development: analysis of brain natriuretic peptide serum levels in HCV/HIV-coinfected and HIV-monoinfected patients. Eur J Gastroenterol Hepatol. 2012 Nov;24(11):1308-12.

http://www.ncbi.nlm.nih.gov/pubmed/22825646

Hepatic safety of injectable extended-release naltrexone in patients with chronic hepatitis C and HIV infection. Mitchell MC, Memisoglu A, Silverman BL. J Stud Alcohol Drugs. 2012 Nov;73(6):991-7.

http://www.ncbi.nlm.nih.gov/pubmed/23036218

Ribavirin and abacavir drug interaction in HIV-HCV coinfected patients: fact or fiction?

Solas C, Pambrun E, Winnock M, et al. AIDS. 2012 Nov 13;26(17):2193-2199.

http://www.ncbi.nlm.nih.gov/pubmed/22781224

Complementary and Alternative Medicine

Limited Sampling Estimates of Epigallocatechin Gallate Exposures in Cirrhotic and Noncirrhotic Patients With Hepatitis C After Single Oral Doses of Green Tea Extract.

Halegoua-De Marzio D, Kraft WK, et al. Clin Ther. 2012 Nov 12. pii: S0149-2918(12)00614-5. doi: 10.1016/j.clinthera.2012.10.009. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23153661

Epidemiology, Diagnostics, and Miscellaneous Works

Chronic hepatitis B and C: Exploring perceived stigma, disease information, and health-related quality of life. Drazic YN, Caltabiano ML. Nurs Health Sci. 2012 Nov 22. doi: 10.1111/nhs.12009. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23171324

Distribution of hepatitis C virus genotypes in a diverse US integrated health care population. Manos MM, Shvachko VA, Murphy RC, Arduino JM, Shire NJ. J Med Virol. 2012 Nov;84(11):1744-50. doi: 10.1002/jmv.23399.

http://www.ncbi.nlm.nih.gov/pubmed/22997077

Screening for Hepatitis C Virus Infection in Adults: A Systematic Review to Update the 2004 U.S. Preventive Services Task Force Recommendation. Chou R, Cottrell EB, Wasson N, Rahman B, Guise JM. Ann Intern Med. 2012 Nov 27. doi: 10.7326/0003-4819-158-2-201301150-00574. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23183613

Hepatitis C Testing, Infection, and Linkage to Care Among Racial and Ethnic Minorities in the United States, 2009-2010. Tohme RA, Xing J, Liao Y, Holmberg SD. Am J Public Health. 2012 Nov 15. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23153151

Liver Cancer

Characteristics of elderly hepatitis C virus-associated hepatocellular carcinoma patients.

Kumada T, Toyoda H, Kiriyama S, et al. J Gastroenterol Hepatol. 2012 Nov 28. doi: 10.1111/jgh.12057. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23190084

Lysophospholipid variants in hepatocellular carcinoma. Skill NJ, Jianmin W, Yan X, Zhao Z, Tector AJ, Maluccio MA. J Surg Res. 2012 Nov 8. pii: S0022-4804(12)00959-6. doi: 10.1016/j.jss.2012.10.037. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23158405

Low Hepatitis C Viral Load Predicts Better Long-Term Outcomes in Patients Undergoing Resection of Hepatocellular Carcinoma Irrespective of Serologic Eradication of Hepatitis C Virus. Shindoh J, Hasegawa K, Matsuyama Y, et al. J Clin Oncol. 2012 Nov 5. [Epub ahead of print]

www.ncbi.nlm.nih.gov/pubmed/23129744

Evaluation of the C3435T polymorphism in the MDR1 gene in patients with hepatocellular carcinoma . Baldissera VD, de Mat AA, Coral GP, et al. Ann Hepatol. 2012 Nov;11(6):899-906.

http://www.ncbi.nlm.nih.gov/pubmed/23109454